The drug: Alpharadin
The disease: Cancer
The developers: Bayer, Algeta
Peak sales potential: $1 billion-plus

Just days ago, Alpharadin was back in the news with new data analyses indicating that it could have broad use in prostate cancer. Investigators have been studying Alpharadin, or radium-223 dichloride, as a potential treatment for bone metastases that result from prostate cancer.

The treatment has already produced solid survival data as well as evidence of delayed bone metastases. The drug earned some serious kudos at a major European cancer meeting last year.

For Bayer, which struck an $800 million licensing pact on Alpharadin three years ago, its clinical success is supremely important. Bayer, which markets Nexavar in partnership with Onyx ($ONXX), also just scored an approval for regorafenib (now Stivarga). Another approval in cancer would go a long way to demonstrating its success in building a multiproduct cancer franchise. And company execs couldn't be happier about its prospects.

Not all analysts, though, are quite so sure that Alpharadin will join the blockbuster club. But it will likely get its shot.

For more:
Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field
Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful
Bayer snares Algeta's lead cancer med in $800M pact
Bayer, Onyx nab speedy FDA OK for regorafenib, prices at $9,350


Suggested Articles

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The series B round equips Oncorus to move its lead asset into the clinic and nominate an intravenously administered viral candidate early next year.

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.